Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Avantor Inc. (AVTR) Stock Forecast & Price Prediction United States | NYSE | Healthcare | Medical Instruments & Supplies
$11.38
-0.32 (-2.74%)Did AVTR Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Avantor is one of their latest high-conviction picks.
Based on our analysis of 32 Wall Street analysts, AVTR has a neutral consensus with a median price target of $13.00 (ranging from $12.00 to $19.00). The overall analyst rating is Buy (7.1/10). Currently trading at $11.38, the median forecast implies a 14.2% upside. This outlook is supported by 5 Buy, 13 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Luke Sergott at Barclays, suggesting a 5.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for AVTR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 30, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $14.00 |
| Oct 30, 2025 | Barclays | Luke Sergott | Equal-Weight | Downgrade | $12.00 |
| Oct 30, 2025 | JP Morgan | Casey Woodring | Neutral | Downgrade | $12.00 |
| Oct 24, 2025 | Baird | Catherine Schulte | Outperform | Maintains | $17.00 |
| Oct 16, 2025 | Raymond James | Andrew Cooper | Outperform | Maintains | $16.00 |
| Oct 2, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $15.00 |
| Aug 4, 2025 | Stifel | Daniel Arias | Hold | Maintains | $12.00 |
| Aug 4, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $12.00 |
| Aug 4, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $17.00 |
| Aug 4, 2025 | JP Morgan | Rachel Vatnsdal | Overweight | Maintains | $14.00 |
| Aug 4, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $16.00 |
| Aug 4, 2025 | Raymond James | Andrew Cooper | Outperform | Reiterates | $14.00 |
| Aug 4, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $13.00 |
| Aug 4, 2025 | Baird | Catherine Schulte | Outperform | Maintains | $15.00 |
| Aug 4, 2025 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $16.00 |
| Jul 28, 2025 | Baird | Catherine Schulte | Outperform | Maintains | $18.00 |
| Apr 29, 2025 | Goldman Sachs | Matthew Sykes | Neutral | Downgrade | $14.00 |
| Apr 28, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $15.00 |
| Apr 28, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Downgrade | $15.00 |
| Apr 28, 2025 | Baird | Catherine Schulte | Outperform | Maintains | $17.00 |
The following stocks are similar to Avantor based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Avantor Inc. has a market capitalization of $7.76B with a P/E ratio of 14.9x. The company generates $6.58B in trailing twelve-month revenue with a -1.3% profit margin.
Revenue growth is -5.3% quarter-over-quarter, while maintaining an operating margin of +8.5% and return on equity of -1.5%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Provider of critical products for life sciences.
Avantor Inc. generates revenue by supplying a comprehensive range of laboratory chemicals, consumables, equipment, and instrumentation to various sectors, including life sciences, advanced technologies, and applied materials. The company serves a diverse clientele, including pharmaceutical, biotechnology, academic, and government institutions, facilitating their research, development, and manufacturing processes.
Operating in over 30 countries, Avantor's integrated solutions support scientific applications that enhance healthcare and public welfare. The company's focus on sustainability and compliance strengthens its market position as a trusted supplier in essential science and technology products.
Healthcare
Medical Instruments & Supplies
13,500
Mr. Emmanuel Ligner
United States
2019
A class action lawsuit has been filed against Avantor, Inc. (NYSE: AVTR) and its officers, as announced by law firm Bronstein, Gewirtz & Grossman, LLC on Nov. 13, 2025.
A class action lawsuit against Avantor could lead to financial liabilities and reputational damage, potentially affecting stock performance and investor returns.
Investors in Avantor, Inc. (NYSE: AVTR) have until December 29, 2025, to file a lead plaintiff motion in a class action for shares acquired between March 5, 2024, and October 28, 2025.
The deadline for filing a lead plaintiff motion in the Avantor class action could impact share value and investor recoveries, influencing market sentiment and trading strategies.
A class action lawsuit has been filed against Avantor, Inc. (NYSE: AVTR) for securities violations. Affected investors from March 5, 2024, to October 28, 2025, should contact Schall Law Firm by December 29, 2025.
The class action lawsuit against Avantor could lead to financial liabilities and impact the company's stock price, affecting current and potential investors' positions.
A securities class action lawsuit has been filed against Avantor, Inc. (NYSE: AVTR) on behalf of investors who purchased shares between March 5, 2024, and October 28, 2025.
A class action lawsuit against Avantor could signal potential financial liabilities, impacting stock performance and investor sentiment in the company.
Levi & Korsinsky, LLP has announced a class action securities lawsuit against Avantor, Inc. (NYSE: AVTR), notifying investors of the legal proceedings.
A class action lawsuit against Avantor, Inc. could lead to financial repercussions, affecting stock value, investor confidence, and potential liabilities for the company.
Avantor, Inc. (NYSE: AVTR) investors who experienced losses may explore recovery options under federal securities laws. More information is available via the provided link.
The news indicates potential legal action against Avantor, Inc., which could impact stock value and investor sentiment, signaling risks associated with the companyโs financial integrity.
Based on our analysis of 32 Wall Street analysts, Avantor Inc. (AVTR) has a median price target of $13.00. The highest price target is $19.00 and the lowest is $12.00.
According to current analyst ratings, AVTR has 5 Buy ratings, 13 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.38. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict AVTR stock could reach $13.00 in the next 12 months. This represents a 14.2% increase from the current price of $11.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
Avantor Inc. generates revenue by supplying a comprehensive range of laboratory chemicals, consumables, equipment, and instrumentation to various sectors, including life sciences, advanced technologies, and applied materials. The company serves a diverse clientele, including pharmaceutical, biotechnology, academic, and government institutions, facilitating their research, development, and manufacturing processes.
Price targets from Wall Street analysts for AVTR are not currently available. The stock is trading at $11.38.
The lowest price target for AVTR is $12.00 from Luke Sergott at Barclays, which represents a 5.4% increase from the current price of $11.38.
The overall analyst consensus for AVTR is neutral. Out of 32 Wall Street analysts, 5 rate it as Buy, 13 as Hold, and 0 as Sell, with a median price target of $13.00.
Stock price projections, including those for Avantor Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.